NCT07190677unknownrecruiting

First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial)

Fondazione IRCCS Policlinico San Matteo di Pavia

ClinicalTrials.gov

300

Enrollment · estimated

Countries · 1 sites

2025-12

Primary completion

11 mo ago

Record updated

Commercial relevance

No explicit biomarker / molecular-testing language identified in the public record.

Change timeline

No changes detected yet. The first refresh records a baseline snapshot; subsequent refreshes generate field-level changes.

Signals from this trial

New trial
32/100
Opportunity
New unknown trial NCT07190677 posted by Fondazione IRCCS Policlinico San Matteo di Pavia: "First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial)".
ClinicalTrials.gov record updated 349 days ago.

Eligibility — raw, for validation

Inclusion Criteria:

* Diagnosis of stage IV or recurrent NSCLC (histologically or cytologically confirmed stage);
* Decision to initiate a first-line treatment with nivolumab plus ipilimumab in combination with 2 cycles of platinum-based chemotherapy for the treatment of NSCLC according to the Italian label, independently of the study, in patients whose tumors have no sensitising EGFR mutation or ALK translocation;
* Patient is at least 18 years of age at time of treatment decision;
* Patient provided written informed consent to participate in the study.

Exclusion Criteria:

* Current primary diagnosis of a cancer other than NSCLC that requires systemic or other treatment;
* Previous treatment with nivolumab and/or ipilimumab;
* Patient already included in an interventional clinical trial for their advanced or recurrent NSCLC.